

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**(Under 37 CFR 1.97(b) or 1.97(e))**

Docket No.

14438

In Re Application Of: **Richard J. Lewis, et al.**

Serial No.

09/787,986

Filing Date

March 23, 2001

Examiner

Unassigned

Group Art Unit

Unassigned

Title: **NOVEL PEPTIDES**

Address to:

**Assistant Commissioner for Patents
Washington, D.C. 20231****37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
2. a Notice of Allowance under 37 CFR 1.311,

whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

OR

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

14438

In Re Application Of: Richard J. Lewis, et al.



Serial No.

09/787,986

Filing Date

March 23, 2001

Examiner

Unassigned

Group Art Unit

Unassigned

Title: NOVEL PEPTIDES

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

_____) on _____
(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Mishelle Mustafa

Typed or Printed Name of Person Mailing Correspondence

*This certificate may only be used if paying by deposit account.

Signature

Dated: October 30, 2001

Frank S. DiGiglio
Registration No. 31,346

Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, NY 11530
(516) 742-4343

CC:



PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Richard J. Lewis, et al.

Examiner: Unassigned

Serial No: 09/787,986

Art Unit: Unassigned

Filed: March 23, 2001

Docket: 14438

For: NOVEL PEPTIDES

Dated: October 30, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. Yaksh, T.L., "Pharmacology of Spinal Adrenergic Systems Which Modulate Spinal Nociceptive Processing", Pharmacology Biochemistry & Behavior 22: 845-858 (1985);
2. Yaksh T.L. & Takano, Y. "Characterization of the Pharmacology of Intrathecally Administered Alpha-2 Agonists and Antagonists in Rats", J. Pharmacology & Experimental Therapeutics 261(2): 764-772 (1992);
3. Yaksh, T.L. & Howe, J.R., "Changes in Sensitivity to Intrathecal Norepinephrine and Serotonin after 6-Hydroxydopamine (6-OHDA), 5,6-Dihydroxytryptamine (5,6-DHT) or Repeated Monoamine Administration", J. Pharmacology & Experimental Therapeutics 220(2): 311-321 (1982);
4. Howe, J.R., et al., "Selective Antagonism of the Antinociceptive Effect of Intrathecally Applied Alpha Adrenergic Agonists by Intrathecal Prazosin and Intrathecal Yohimbine", J. Pharmacology & Experimental Therapeutics 224(3): 552-558 (1983);

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on October 30, 2001.

Dated: October 30, 2001


Mishelle Mustafa


5. Solomon, et al., "Pharmacological Characterization of Alpha Adrenoceptors Involved in the Antinociceptive and Cardiovascular Effects of Intrathecally Administered Clonidine", J. Pharmacology & Experimental Therapeutics 251(1): 28-38 (1989);
6. Fleetwood-Walker, S.M. et al., "An α_2 Receptor Mediates the Selective Inhibition by Noradrenaline Responses of Identified Dorsal Horn Neurones", Brain Research 334: 243-254 (1985);
7. Sawynok, J. et al., "Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat", Pain 82(2): 149-158 (August 1999);
8. Ardid, D. et al., "Comparative effects of different uptake inhibitor antidepressants in two pain test in mice", Fundam. Clin. Pharmacology 6(2): 75-82 (1992);
9. Kawamata, et al., "Analgesic effect of intrathecal desipramine on carrageenan-induced thermal hyperalgesia in the rat", Br. J. Anaesth 83(3): 449-452 (September 1999)
10. Reimann, et al., "The Antinociceptive Effects of Morphine, Desipramine, and Serotonin and Their Combinations After Intrathecal Injection in the Rat", Anesth Analg 88(1): 141-145 (January 1999)
11. International Patent Application No. WO 00/44769; published August 3, 2000.

Applicants are submitting copies of the above-cited references. All of the references are in English, therefore, no translations are required.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. §1.97(b), no petition, certification or fee is required.

Consideration of this Information Disclosure Statement is respectfully requested.

Respectfully submitted,



Frank S. DiGiglio
Registration No. 31,346

Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, New York 11530
FSD:PIB:lf